Drug Profile
LC 280391
Alternative Names: LC-280391Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in China (unspecified route)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China
- 28 Aug 2015 LC 280391 is available for licensing as of 28 Aug 2015. http://china.lgls.com/